Abstract:Amantadine and modafinil are neurostimulants that may improve cognitive and functional recovery post-stroke, but the existing study results vary, and no comprehensive review has been published. This systematic review describes amantadine and modafinil administration practices post-stroke, evaluates timing and impact on clinical effectiveness measures, and identifies the incidence of potential adverse drug effects. A librarian-assisted search of the MEDLINE (PubMed) and EMBASE databases identified all English-language publications with "amantadine" or "modafinil" in the title or abstract from inception through February 1, 2020. Publications meeting predefined Patient, Intervention, Comparator, Outcome (PICO) criteria were included: Patients (≥ 18 years of age post-stroke); Intervention (amantadine or modafinil administration); Comparison (pretreatment baseline or control group); Outcomes (cognitive or functional outcome). Amantadine and modafinil administration practices, cognitive and functional outcomes, and incidence of potential adverse drug effects were collected following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidance. Quantitative analyses were not performed due to heterogeneity in the clinical effectiveness measures; descriptive data are presented as number (percent) or median (interquartile range). Of 12,620 publications initially identified, 10 amantadine publications (n = 121 patients) and 12 modafinil publications (n = 120 patients) were included. Amantadine was initiated 39 (16, 385) days post-stroke, with most common initial doses of 100 mg once or twice daily (range 100-200 mg/day), and final daily dose of 200 (188, 200) mg/day. Modafinil was initiated 170 (17, 496) days post-stroke, with initial and final daily doses of 100 (100, 350) mg/day and 200 (100, 350) mg/day, respectively. The most common indication was consciousness disorders for amantadine (n = 3/10 publications; 30%) and fatigue for modafinil (n = 5/12; 42%). Forty unique clinical effectiveness measures (1.8 per study) with 141 domains (6.4 per study) were described across all studies. A positive response in at least one clinical effectiveness measure was reported in 70% of amantadine publications and 83% of modafinil publications. Only one publication each for amantadine (10%; n = 5 patients) and modafinil (8%; n = 21 patients) studied acutely hospitalized or ICU patients; both were randomized studies showing improvements in neurocognitive function for amantadine and fatigue for modafinil. Potential adverse drug effects were reported in approximately 50% of publications, most commonly visual hallucinations with amantadine (2% of patients) and dizziness (5% of patients) and dry eyes or mouth (5% of patients). Amantadine and modafinil may improve cognitive and functional recovery post-stroke, but higher-quality data are needed to confirm this conclusion, especially in the acute care setting.

Amantadine treatment is associated with improved consciousness in patients with non-traumatic brain injury

Persistent vegetative state after severe cerebral hemorrhage treated with amantadine: A retrospective controlled study

A Randomized Controlled Trial Measuring Changes in Cerebral Blood Flow after Levetiracetam in Patients with Alzheimer’s Disease

The effect of amantadine treatment on neurological outcome and mortality in mechanically ventilated severe head trauma patients in intensive care unit

Early Amantadine Treatment Reduces the Risk of Death in Patients With Large Hemisphere Infarctions

Early Amantadine Treatment Reduces the Risk of Death in Patients with Large Hemisphere Infarctions:A Chinese Hospital-Based Study

The effects of amantadine on traumatic brain injury outcome: a double-blind, randomized, controlled, clinical trial

Amantadine, apomorphine and zolpidem in the treatment of disorders of consciousness

Additive effect of cerebrolysin and amantadine on disorders of consciousness secondary to acquired brain injury: A retrospective case-control study

Amantadine improves water maze performance without affecting motor behavior following traumatic brain injury in rats

Amantadine and Modafinil as Neurostimulants Following Acute Stroke: A Retrospective Study of Intensive Care Unit Patients

The use of amantadine in patients with unresponsive wakefulness syndrome after severe cerebral hemorrhage

Amantadine for Traumatic Brain Injury—Supporting Evidence and Mode of Action

Informing future randomized controlled trials of amantadine hydrochloride in neurocritical care and post-neurocritical care stroke patients through a retrospective study

Amantadine and Modafinil as Neurostimulants During Post-stroke Care: A Systematic Review

Does amantadine maintain function in long-established brain injury? A single case experimental design

Amantadine and memantine: a comprehensive review for acquired brain injury

Amantadine Preserves Dopamine Level and Attenuates Depression-Like Behavior Induced by Traumatic Brain Injury in Rats.

Therapeutic interventions in patients with prolonged disorders of consciousness

Effects of Amantadine Sulfate on Motor Impairment and Execution of Motor Sequences in Patients With Parkinson Disease

Amantadine Alleviates Postoperative Cognitive Dysfunction Possibly by Increasing Glial Cell Line-Derived Neurotrophic Factor in Rats.